scholarly journals Real-world Effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S Vaccines Against SARS-CoV-2 in Solid Organ and Islet Transplant Recipients

2022 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Chris J. Callaghan ◽  
Lisa Mumford ◽  
Rebecca M. K. Curtis ◽  
Sarah V. Williams ◽  
Heather Whitaker ◽  
...  
Keyword(s):  
Real World ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Islet Transplant

260-LB: Continuous Glucose Monitoring Metrics in Islet Transplant Recipients with Long-Term Insulin Independence

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 260-LB ◽  
Author(s):  
DAVID BAIDAL ◽  
ANA M. ALVAREZ GIL ◽  
NATHALIA PADILLA ◽  
CAMILLO RICORDI ◽  
RODOLFO ALEJANDRO
Keyword(s):  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Transplant Recipients ◽  
Insulin Independence ◽  
Islet Transplant

362-OR: The Biological Variability of the BETA-2 Score in Islet Transplant Recipients

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 362-OR
Author(s):  
ROBYN MILLOTT ◽  
RICHARD A. ORAM ◽  
SHAREEN FORBES ◽  
A.M. JAMES SHAPIRO ◽  
PETER A. SENIOR ◽  
...  
Keyword(s):  
Biological Variability ◽  
Transplant Recipients ◽  
Islet Transplant ◽  
Beta 2

Cytomegalovirus in Solid Organ Transplant Recipients: Clinical Updates, Challenges and Future Directions

2020 ◽  
Vol 26 (28) ◽  
pp. 3497-3506
Author(s):  
Raymund R. Razonable
Keyword(s):  
Organ Transplantation ◽  
Solid Organ Transplantation ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Cmv Infection ◽  
Future Directions ◽  
Prevention And Treatment ◽  
Solid Organ Transplant Recipients

Cytomegalovirus is the classic opportunistic infection after solid organ transplantation. This review will discuss updates and future directions in the diagnosis, prevention and treatment of CMV infection in solid organ transplant recipients. Antiviral prophylaxis and pre-emptive therapy are the mainstays of CMV prevention, but they should not be mutually exclusive and each strategy should be considered depending on a specific situation. The lack of a widely applicable viral load threshold for diagnosis and preemptive therapy is emphasized as a major factor that should pave the way for an individualized approach to prevention. Valganciclovir and intravenous ganciclovir remain as drugs of choice for CMV management, and strategies for managing drug-resistant CMV infection are enumerated. There is increasing use of CMV-specific cell-mediated immune assays to stratify the risk of CMV infection after solid organ transplantation, and their potential role in optimizing CMV prevention and treatment efforts is discussed.

Greater Susceptibility for Metabolic Syndrome in Pediatric Solid Organ and Stem Cell Transplant Recipients

2019 ◽  
Vol 103 (11) ◽  
pp. 2423-2433
Author(s):  
Ricarda Blöte ◽  
Nima Memaran ◽  
Bianca Borchert-Mörlins ◽  
Daniela Thurn-Valsassina ◽  
Imeke Goldschmidt ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Stem Cell ◽  
Stem Cell Transplant ◽  
Solid Organ ◽  
Cell Transplant ◽  
Transplant Recipients
Sign in / Sign up

Export Citation Format

Share Document